Best US Health Care Stocks to Invest In
AI-curated Health Care stock ideas for the US market, each with a buy signal, future-value target and a short thesis. Refreshed every weekday from end-of-day data.
20 picks · prices as of close 2026-07-28
Eli Lilly and Company
Dominant obesity and diabetes pipeline supports durable growth, pricing power, and long runway for earnings expansion.
▸Strong momentum, repeated analyst bullishness, and obesity franchise catalysts.
Novo Nordisk A/S
GLP-1 leadership and global demand remain powerful, with valuation attractive versus long-term growth prospects.
▸GLP-1 demand, expanding capacity, and ongoing institutional accumulation.
Intuitive Surgical, Inc.
Robotic surgery installed-base growth and procedure expansion support steady upside with premium quality.
▸Positive procedure trends and sustained analyst confidence.
Thermo Fisher Scientific Inc.
Life-science tools recovery and resilient cash generation offer attractive forward value and catalyst leverage.
▸Analyst upgrades and improving end-market sentiment.
Danaher Corporation
Diagnostics and bioprocessing normalization create a strong earnings rebound setup over the next year.
▸Recovery catalysts and institutional sponsorship remain supportive.
Vertex Pharmaceuticals Incorporated
Cystic fibrosis cash flow plus new launch optionality make it a high-quality growth compounder.
▸Pipeline catalysts and durable earnings momentum.
Boston Scientific Corporation
Strong med-tech execution, recurring procedure growth, and margin expansion support continued upside.
▸Breakout momentum and favorable analyst revisions.
Stryker Corporation
Defensive med-tech leadership and consistent growth make it attractive despite a premium valuation.
▸Solid momentum and steady institutional support.
Zoetis Inc.
Animal health resilience and pricing strength offer dependable earnings growth and lower cyclicality.
▸Defensive demand and improving sentiment after valuation compression.
Veeva Systems Inc.
Best-in-class healthcare software growth and sticky subscription revenue support long-term compounding.
▸Margin expansion and strong momentum in subscription analytics.
GE HealthCare Technologies Inc.
Imaging and diagnostics improvement plus valuation support create a favorable risk-reward setup.
▸Operational execution and multiple expansion potential.
Abbott Laboratories
Diversified diagnostics, devices, and nutrition provide consistent growth with defensive stability.
▸Reliable earnings trend and broad healthcare demand.
Medtronic plc
Turnaround in devices and cost discipline can unlock incremental upside from a reasonable base.
▸Turnaround catalysts and improving analyst sentiment.
The Cigna Group
Managed-care scale, buyback support, and valuation discount make it attractive on forward returns.
▸Shareholder returns and favorable valuation setup.
UnitedHealth Group Incorporated
Scale and cash generation remain elite, with recovery potential if sentiment normalizes.
▸Deep value relative to history and eventual sentiment recovery.
Bristol-Myers Squibb Company
Pipeline progress and capital returns support a value-oriented healthcare allocation.
▸Low valuation, buybacks, and pipeline catalysts.
Merck & Co., Inc.
Strong oncology franchise and pipeline execution provide a solid earnings and catalyst profile.
▸Pipeline events and steady institutional support.
CVS Health Corporation
Turnaround value remains compelling if margin repair and healthcare services execution continue.
▸Operational turnaround and valuation reset.
Gilead Sciences, Inc.
Solid cash flow, oncology growth, and attractive valuation support moderate upside.
▸Income support and improving growth visibility.
TransMedics Group, Inc.
High-growth organ transport platform offers outsized upside, though with higher execution risk.
▸Strong momentum and expanding adoption of a differentiated platform.